Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab for HPR in ASCVD
NCT03096288Phase 4Completed
- Sponsor
- University of Florida
- Start
- Oct 2017
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in atherosclerotic cardiovascular disease (ASCVD) comparing Evolocumab with Placebo (2 arms). Primary endpoint: P2Y12 Reaction Units at 30 days. Started Oct 2017; status: completed.
02
Drugs
evolocumab
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT03096288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03096288.